Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 2/20 | 0.59 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.57 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.57 |
| ▸ | ESR1 | P03372 | 2/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.57 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.57 |
| ▸ | TUBB | P07437 | 2/20 | 0.57 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.57 |
| ▸ | AHR | P35869 | 2/20 | 0.57 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.57 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.57 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.57 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.57 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.57 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.57 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.57 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.57 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3087934 | 1.00 | RELA (0.59) | RELATRPA1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL1099 | 0.87 | CA1 (0.58) | KDM4ECYP3A4ALDH1A1NPC1RAB9A | |
| SCHEMBL13247235 | 0.83 | RELA (0.63) | RELATRPA1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL631998 | 0.82 | RELA (0.81) | RELATRPA1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL9408115 | 0.82 | FFAR1 (0.39) | CYP1A2AHRCYP19A1NFE2L2KDM4E | |
| SCHEMBL14950253 | 0.82 | RELA (0.81) | RELATRPA1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL13790336 | 0.82 | RELA (0.81) | RELATRPA1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL4881152 | 0.82 | RELA (0.81) | RELATRPA1CYP1A2CYP1A1CYP1B1 | |
| SCHEMBL9408109 | 0.82 | FFAR1 (0.39) | CYP1A2AHRCYP19A1NFE2L2KDM4E | |
| SCHEMBL699458 | 0.82 | RELA (0.81) | RELATRPA1CYP1A2CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790744-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20050181984-A1 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY | 2005-08-18 | — | — | US | disclosed |
| US-6916784-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-6743777-B1 | TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20030220236-A1 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY | 2003-11-27 | — | — | US | disclosed |
| EP-0744405-B1 | Cyclic peptide antifungal agents | LILLY CO ELI (US) | 2003-07-16 | — | — | EP | disclosed |
| EP-0736541-B1 | Cyclic hexapeptide antifungal agents | LILLY CO ELI (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-0561639-B1 | Cyclic peptide antifungal agents and process for preparation thereof | LILLY CO ELI (US) | 2002-05-15 | — | — | EP | disclosed |
| US-6384013-B1 | HETEROCYCLIC PEPTIDE FUNGICIDES | ELI LILLY AND COMPANY | 2002-05-07 | — | — | US | disclosed |
| US-5965525-A | FOR INHIBITING FUNGAL AND PARASITIC ACTIVITIES | ELI LILLY AND COMPANY (US) | 1999-10-12 | — | — | US | disclosed |
| CN-1185739-A | Cyclic peptide fungicides | ELI LILLY AD COMPANY (US) | 1998-06-24 | — | — | CN | disclosed |
| CN-1036715-C | Cyclic peptide antifungal agents and process for preparation thereof | LILLY CO ELI (US) | 1997-12-17 | — | — | CN | disclosed |
| US-5652213-A | CYCLIC HEXAPEPTIDE FUNGICIDES, PARASITICIDES | ELI LILLY AND COMPANY (US) | 1997-07-29 | — | — | US | disclosed |
| US-5646111-A | Cyclic peptide antifungal Agents | ELI LILLY AND COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1996037510-A1 | CYCLIC PEPTIDE ANTIFUNGAL AGENTS | ELI LILLY AND COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |
| EP-0744405-A2 | Cyclic peptide antifungal agents | ELI LILLY AND COMPANY (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1996031228-A1 | CYCLIC PEPTIDE ANTIFUNGAL AGENTS | ELI LILLY AND COMPANY (US) | 1996-10-10 | — | — | WO | disclosed |
| EP-0736541-A1 | Cyclic hexapeptide antifungal agents | ELI LILLY AND COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| CN-1080926-A | Cyclic peptide antifungal agents and preparation method thereof | LILLY CO ELI (US) | 1994-01-19 | — | — | CN | disclosed |
| EP-0561639-A1 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 1993-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220236-A1 | Cyclic peptide antifungal agents and process for preparation thereof | NGLY1, HM13, PTMS | RELA 4183/4885TRPA1 4846/4885CYP1A2 3163/4885 |
| US-20050181984-A1 | Cyclic peptide antifungal agents and process for preparation thereof | NGLY1, PTMS, HM13 | RELA 3605/4885TRPA1 4823/4885CYP1A2 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.